Laidlaw & Co. Downgrades MEI Pharma to Hold
Portfolio Pulse from Benzinga Newsdesk
Laidlaw & Co. analyst Yale Jen has downgraded MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
July 23, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Laidlaw & Co. analyst Yale Jen has downgraded MEI Pharma from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on MEI Pharma's short-term prospects, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100